CONFIRMED SPEAKERS

Matthew Johnson
MATTHEW JOHNSON, PhD

Psychedelics as Behavior Change Agents

Alicia Danforth
ALICIA DANFORTH, PhD

Advancing the Ethics of Psychedelic Medicine and Psychotherapy

RICK DOBLIN, PhD

FDA & EMA Development of MDMA-assisted Psychotherapy for PTSD

Janis Phelps
JANIS PHELPS, PhD

Training Future Psychedelic Therapists

Ben Sessa
BEN SESSA, MD

MDMA-assisted psychotherapy for alcoholism

Michael Mithoefer
MICHAEL MITHOEFER, MD

MDMA-assisted psychotherapy for PTSD: updates & observations

Alexander Belser
ALEXANDER BELSER, PhD

Psychedelic Therapy for Gender and Sexual Minorities

Elizabeth Nielson
ELIZABETH NIELSON, PhD

Psilocybin-Assisted Treatment of Alcohol Use Disorder

Francisco Moreno
FRANCISCO MORENO, MD

Psilocybin versus placebo in Treatment Resistant OCD

Leor Roseman
LEOR ROSEMAN, PhD

Palestinians, Israelis, and Ayahuasca: can psychedelics promote reconciliation?

Christopher Timmermann
CHRISTOPHER TIMMERMANN, PhD cand

DMT: Neuroscience, phenomenology and therapeutic potential

MATTHEW JACKSON

Patient Perspectives from a Psilocybin for Depression Trial

Jordan Sloshower
JORDAN SLOSHOWER, MD

Psilocybin-assisted therapy of MDD using Acceptance and Commitment Therapy

Sophia Korb & James Fadiman
JAMES FADIMAN, PhD & SOPHIA KORB, PhD

Unexpected results of crowd-sourced microdosing research

Enzo Tagliazucchi
ENZO TAGLIAZUCCHI, PhD

Neural and psychological correlates of inhaled DMT in naturalistic settings

David Nicolas Langlitz
NICOLAS LANGLITZ, PhD

The Paradoxes of Psychedelic Humanities

Alan Kooi Davis
ALAN KOOI DAVIS, PhD

Psychedelic-occasioned decreases in trauma among people of color

Ido Hartogsohn
IDO HARTOGSOHN, PhD

Psychedelics, Set and setting, Meaning-Enhancement and Placebo Response

Torsten Passie
TORSTEN PASSIE, MD, PhD

Low-Dose Psycholytic Therapy: A Neglected Approach?

Fernanda Palhano Xavier de Fontes
FERNANDA PALHANO-FONTES, PhD

Findings from an RCT with ayahuasca for TRD

Mendel Kaelen
MENDEL KAELEN, PhD

Music for/as Psychedelic Therapy

Friederike Holze
FRIEDERIKE HOLZE, PhD cand

LSD dose response - a double-blind cross-over study in healthy subjects

Luís Fernando Tófoli
LUIS F. TOFOLI, MD, PhD

An interdisciplinary discussion on the integration of the psychedelic experience

Daniela Peluso
DANIELA PELUSO, PhD

The emergence of global ayahuasca

Lucas de Oliveira Maia
LUCAS DE OLIVEIRA MAIA, PhD

Therapeutic effects of ayahuasca by people facing severe physical illness

Leopardo
LEOPARDO YAWA BANE

The uses of Nixi pae in the Huni Kui tradition

Adam Aronovich
ADAM ARONOVICH, PhD cand

Ayahuasca as Relational Medicine

Juan Flores
JUAN FLORES

Material and immaterial constitutive elements of healing sites - Mayantuyacu

Nadia Hutten
NADIA HUTTEN, PhD cand

Cognitive and subjective effects of LSD in a placebo-controlled study

Emmanuelle A. D. Schindler
EMMANUELLE SCHINDLER, MD, PhD

Effects of Low Oral Dose of Psilocybin in Migraines

Jeffrey Guss
JEFFREY GUSS, MD

Psilocybin-assisted therapy of depressive disorder using ACT as a therapeutic frame

Daan Keiman
DAAN KEIMAN, MA

Integrating Interfaith Spiritual Care Into Psychedelic Therapies and Science

Malin Uthaug
MALIN UTHAUG, PhD cand

A placebo-controlled study of ayahuasca on mental health in a naturalistic setting

Natasha L Mason
NATASHA L MASON, PhD cand

Acute effects of psilocybin on glutamate, functional connectivity & subjective state

Balazs Szigeti
BALAZS SZIGETI, PhD

Beyond the placebo? An exploration of psychedelics microdosing with self-blinding methodology

Tobias Buchborn
TOBIAS BUCHBORN, PhD cand

Introduction to the pharmacodynamics of repeated psychedelic-drug intake

Sasha Frost
SASHA FROST, MSc

Reframing Psychedelics - Drawing on old metaphors to create new understanding

Eric Sienknecht, Psy.D. and Veronika Gold, MFT
ERIC SIENKNECHT, PsyD & VERONIKA GOLD, MFT

Ketamine-Assisted Psychotherapy: Observations

Michelle Baker Jones
MICHELLE BAKER JONES

Psilocybin treatment for depression – inside perspectives

Henry J Whitfield
HENRY J WHITFIELD, MSc

A longitudinal multiple baseline investigation of psychedelic integration using ACT

Aidan Lyon
AIDAN LYON, PhD

A unified, philosophical account of the mind-revealing effects of psychedelics and meditation

Timo Torsten Schmidt
TIMO TORSTEN SCHMIDT, PhD

fMRI studies of non-pharmacologically induced altered states of consciousness:

Marc Tuters
MARC TUTERS, PhD

Silicon Valley Psychedelia, Then and Now

Ruben Laukkonen
RUBEN LAUKKONEN, PhD

The phenomenology of truth: How the feeling of insight guides decisions under uncertainty

Raphaël Millière
RAPHAËL MILLIÈRE, PhD cand

The Sense of Body Ownership in Drug-Induced States

Katrin Preller
KATRIN PRELLER, PhD

Psilocybin induces time-dependent changes in global brain connectivity

Vincent Verroust
VINCENT VERROUST, PhD cand

The first clinical trials of psilocybin in France (1956-1960)

Metten Somers
METTEN SOMERS, MD PhD

Psilocybin intreatment-resistant depression: clinical experiences

Eduardo Schenberg
EDUARDO SCHENBERG, PhD

Antes o cérebro não existia (Once, the brain did not exist)

Peter Gasser
PETER GASSER, MD

The Development of Psycholytic / Psychedelic Therapy

David Dupuis
DAVID DUPUIS, PhD

The socialization of hallucinations

J.P. TEN BERGE
JOS TEN BERGE, PhD

Drugs in Art: Instant Inspiration or Placebo?

Taylor Lyons
TAYLOR LYONS, PhD cand.

The acute and long-term effects of psilocybin in healthy volunteers

Helle Kaasik
HELLE KAASIK, PhD

Varieties of chemical composition of Ayahuasca.

David de Wied
DAVID DE WIED, MSc

Setting the stage for peak experiences: Mindset, Music and Environment

Sam Gandy
SAM GANDY, PhD

From Egoism to Ecoism: Psychedelics & Nature Connection

WOUTER J. HANEGRAAFF
WOUTER HANEGRAAFF, PhD

Psychedelics as Rejected Knowledge

Michiel van elk
MICHIEL VAN ELK, PhD

Effects of Psilocybin Microdosing on Awe and Aesthetic Experiences

Tim Read
TIM READ, MD

The Dark Place: a comprehensive model for psychedelic psychotherapy

Gemma Blok
GEMMA BLOK, PhD

"IBOGAINE TESTING NOW!” Western Ibogaine activism around 1990

Hannes Kettner
HANNES KETTNER, MSc

Learning from uncertainty: Relax your priors and trust in the unknown

Lynnette A Averill
LYNNETTE AVERILL, PhD

Psychedelic treatments for cognitive impairment, PTSD, depression among veterans

Simon Ruffell
SIMON RUFFELL, MD

Modulatory Effects of Ayahuasca on Personality Structure in an Adapted Traditional Framework

Olivia Rose Marcus
OLIVIA ROSE MARCUS, PhD c.

Traditionalizing global forms: ethics in vegetalista practices of the Peruvian Amazon

Tomas Palenicek
TOMAS PALENICEK, MD, PhD

Expedition Neuron: a journey towards the neurobiology of ayahuasca in a naturalistic setting

Anja Katharina Loizaga-Velder
ANJA LOIZAGA-VELDER, PhD

The contribution of indigenous plant medicine traditions to modern psychedelic medicine

Rafael Lancelotta
RAFAEL LANCELOTTA

The Psychotherapeutic Potential of Short-acting Tryptamines

Livia Goto Silva
LIVIA GOTO SILVA, PhD

Potential therapeutic effects of 5-MeO-DMT in brain insulin resistance

Bennet Zelner
BENNET ZELNER, PhD

The Pollination Approach: Psychedelic Therapy in Community Systems

David Luke
DAVID LUKE, PhD

Transpersonal ecodelia: Surveying psychedelically induced biophilia

Elias Dakwar
ELIAS DAKWAR, MD

Ketamine-assisted Treatment of Substance Use Disorders

DAAN OOSTVEEN, PhD

Towards a new materialism in psychedelics studies

Milan Scheidegger
MILAN SCHEIDEGGER, MD, PhD

Pharmahuasca applications for mental health

Ido Siemion
IDO SIEMION, PhD

The Hakomi Method in Psychedelic Therapy: Principles and Interventions

Martin Madsen
MARTIN MADSEN, PhD

Five-hour fMRI mapping after oral psilocybin reveals distinct psilocin-dependent changes in resting state functional connectivity

Nicole Amada
NICOLE AMADA

Narrative Self and the Psychedelic Experience: An exploratory qualitative study

Richard Zeifman
RICHARD ZEIFMAN, PhD

How Does Psilocybin Therapy Work?: Exploring Experiential Avoidance as a Mechanism of Change

Ingmar Gorman
INGMAR GORMAN, PhD

MDMA-assisted Psychotherapy for PTSD: Beyond Symptom Reduction

NEILOUFAR FAMILY, PhD

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Low Dose Lysergic Acid Diethylamide (LSD) in Healthy Volunteers

LUIS FELIPE SEQUEIRA VALÊNCIO
LUIS FELIPE SEQUEIRA VALÊNCIO, PhD

The Role of Research Ethics in the "Psychedelic Renaissance"

Jani Pestana
JANI PESTANA, MSc

Motivations & modalities of psychedelic substance use in Reddit's psychonaut community

CAMILLA DAY
CAMILLA DAY, MD

Compassion Experience Scale in Psilocybin for Treatment Resistant Depression

Gabby Agin-Liebes
GABBY AGIN-LIEBES, PhD c.

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

RICARDA EVENS, PhD

The Afterglow Inventory (AGI) – a new instrument to measure subacute effects of the psychedelic experience

NEWSLETTER

STAY IN TOUCH

Be the first to learn about the ticket sale, speaker announcements and all things ICPR.